The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The current immunotherapeutic landscape for treatment of DLBCL
Christopher Melani, MD, National Institutes of Health, Bethesda, MD, outlines the current immunotherapeutic landscape for diffuse large B-cell lymphoma (DLBCL), and comments on the evolution of treatment in recent years. Although chemotherapy was the standard of care in the front-line setting for over 20 years, this has changed with the approval of polatuzumab vedotin plus R-CHP as a result of data from the POLARIX trial (NCT03274492). In the relapsed/refractory (R/R) setting, the number of therapeutic options for patients has increased, and there is more significant potential for cure. Both CAR T-cell therapy and bispecific antibodies show promising efficacy in pre-treated patients and are being investigated in further trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
